Pharmaceutical composition for the treatment of disorders of non-human mammals
CA 2461092 A1 · Owner: Boehringer Ingelheim International Gmbh · Inventors: Kleemann, Rainer; Bette, Peter; Van Meel, Jacobus
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Pharmaceutical composition for the treatment of disorders in particular for , the treatment of mammary tumors of a non-human mammal which is associated , with an aberrant activity of one or more tyrosine kinase receptors. The composition contains, as the active ingredient one or more substances that , inhibit the aberrant activity of the tyrosine kinase receptor(s) of said animal, in particular the Epidermal Growth Factor Receptor (EGFR) and/or HER2. The pharmaceutical composition is particularly useful for the treatment of dogs.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 1, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 1, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 1, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.